Effect of multimodal chemotherapy on survival of gastric cancer with liver metastasis – a population based analysis

Li, Xinghui; Chen, Zhiqiang; Zhang, Yue; Zhang, Hong; Niu, Haiyan; Zheng, Cheng; Jing, Xiaoying; Qiao, Hui; Wang, Guanhua; Yang, Wenjun

doi:10.3389/fonc.2023.1064790

Cited by 1 publication

(1 citation statement)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, it accounts for 37% of postoperative recurrences in patients with GC who have undergone curative gastrectomy [ 3 ]. Unfortunately, owing to the delayed detection and limited efficacy of current treatments, the prognosis of patients with GC-LM remains extremely poor, with a 5-year over survival rate of less than 10% [ 4 ]. Therefore, it is imperative to further investigate the mechanisms underlying the initial events in GC-LM to identify potential diagnostic markers and effective therapeutic targets for early detection and improved intervention.…”

Section: Introductionmentioning

confidence: 99%

Gastric cancer-derived LBP promotes liver metastasis by driving intrahepatic fibrotic pre-metastatic niche formation

Xie,

Qiu,

et al. 2023

J Exp Clin Cancer Res

View full text Add to dashboard Cite

Background Liver metastasis (LM) is one of the most common distant metastases of gastric cancer (GC). However, the mechanisms underlying the LM of GC (GC-LM) remain poorly understood. This study aimed to identify the tumour-secreted protein associated with GC-LM and to investigate the mechanisms by which this secreted protein remodels the liver microenvironment to promote GC-LM. Methods Data-independent acquisition mass spectrometry (DIA-MS), mRNA expression microarray, quantitative real-time PCR, enzyme-linked immunosorbent assay (ELISA) and immunohistochemistry (IHC) were performed to identify and validate the GC-secreted proteins associated with GC-LM. A modified intrasplenic injection mouse model of LM was used to evaluate the progression and tumour burden of LM in vivo. Flow cytometry, immunofluorescence (IF), western blots (WB) and IHC were performed to validate the pre-metastatic niche (PMN) formation in the pre-modelling mouse models. mRNA sequencing of PMA-treated THP-1 cells with or without lipopolysaccharide binding protein (LBP) treatment was used to identify the functional target genes of LBP in macrophages. Co-immunoprecipitation (Co-IP), WB, ELISA, IF and Transwell assays were performed to explore the underlying mechanism of LBP in inducing intrahepatic PMN formation. Results LBP was identified as a critical secreted protein associated with GC-LM and correlated with a worse prognosis in patients with GC. LBP activated the TLR4/NF-κB pathway to promote TGF-β1 secretion in intrahepatic macrophages, which, in turn, activated hepatic satellite cells (HSCs) to direct intrahepatic fibrotic PMN formation. Additionally, TGF-β1 enhanced the migration and invasion of incoming metastatic GC cells in the liver. Consequently, selective targeting of the TGF-β/Smad signaling pathway with galunisertib demonstrated its efficacy in effectively preventing GC-LM in vivo. Conclusions The results of this study provide compelling evidence that serological LBP can serve as a valuable diagnostic biomarker for the early detection of GC-LM. Mechanistically, GC-derived LBP mediates the crosstalk between primary GC cells and the intrahepatic microenvironment by promoting TGF-β1 secretion in intrahepatic macrophages, which induces intrahepatic fibrotic PMN formation to promote GC-LM. Importantly, selectively targeting the TGF-β/Smad signaling pathway with galunisertib represents a promising preventive and therapeutic strategy for GC-LM.

show abstract

Section: Introductionmentioning

confidence: 99%